Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsKrithika N. KODUMUDI, Brian CZERNIECKI
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-cancer therapies comprising i) at least one dendritic cell pulsed with an oncodriver and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor and methods of the use of said therapies to treat cancer.
Claims16
An anti-cancer combination therapy comprising i) at least one oncodriver pulsed dendritic cell and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor;
- further comprising at least one immunoregulatory molecule inhibitor;
- wherein the immunoregulatory molecule being inhibited comprises Semaphorin (SEMA) 4D (SEMA4D), SEMA4A, SEMA4B, SEMA4C, SEMA4F, SEMA4G, SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F, SEMA3G, or VEGF.
A method of treating a cancer in a subject comprising administering to the subject i) an oncodriver pulsed dendritic cell and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor;
- further comprising administering to the subject at least one immunoregulatory molecule inhibitor;
- wherein the immunoregulatory molecule being inhibited comprises Semaphorin (SEMA) 4D (SEMA4D), SEMA4A, SEMA4B, SEMA4C, SEMA4F, SEMA4G, SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F, SEMA3G, or VEGF.
A method of treating a secondary tumor in a subject comprising administering to site of a primary tumor in the subject i) an oncodriver pulsed dendritic cell and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor;
- further comprising administering to the subject at least one immunoregulatory molecule inhibitor;
- wherein the immunoregulatory molecule being inhibited comprises Semaphorin (SEMA) 4D (SEMA4D), SEMA4A, SEMA4B, SEMA4C, SEMA4F, SEMA4G, SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F, SEMA3G, or VEGF;
- wherein treatment of the primary tumor has an abscopal effect on the secondary tumor.
Dependencies are inferred from the claim text.